These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Combined effect of interleukin 2 and bacillus Calmette-Guérin in the therapy of mice with transitional cell carcinoma. Ikemoto S; Kamizuru M; Wada S; Nishio S; Kishimoto T; Maekawa M Urol Int; 1991; 47(4):250-4. PubMed ID: 1781111 [TBL] [Abstract][Full Text] [Related]
8. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients. Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. Riggs DR; Tarry WF; DeHaven JI; Sosnowski J; Lamm DL J Urol; 1992 Jan; 147(1):212-4. PubMed ID: 1729535 [TBL] [Abstract][Full Text] [Related]
12. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. Herr HW; Schwalb DM; Zhang ZF; Sogani PC; Fair WR; Whitmore WF; Oettgen HF J Clin Oncol; 1995 Jun; 13(6):1404-8. PubMed ID: 7751885 [TBL] [Abstract][Full Text] [Related]
13. Superiority of intravesical immunotherapy with Corynebacterium parvum and Allium sativum in control of murine bladder cancer. Marsh CL; Torrey RR; Woolley JL; Barker GR; Lau BH J Urol; 1987 Feb; 137(2):359-62. PubMed ID: 3806842 [TBL] [Abstract][Full Text] [Related]
14. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. Brake M; Loertzer H; Horsch R; Keller H J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163 [TBL] [Abstract][Full Text] [Related]
15. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729 [TBL] [Abstract][Full Text] [Related]
16. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin. Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815 [TBL] [Abstract][Full Text] [Related]
17. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine. Lee CF; Chang SY; Hsieh DS; Yu DS J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345 [TBL] [Abstract][Full Text] [Related]
19. Prophylaxis and therapy of an experimental bladder cancer with biological response modifiers. Morales A; Pang AS J Urol; 1986 Jan; 135(1):191-3. PubMed ID: 3941461 [TBL] [Abstract][Full Text] [Related]
20. Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in control of murine transitional cell carcinoma. Lau BH; Woolley JL; Marsh CL; Barker GR; Koobs DH; Torrey RR J Urol; 1986 Sep; 136(3):701-5. PubMed ID: 3735559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]